ArticleCancers2020
Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial.
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 10 citations in OpenAlex.
- Myeloid-derived suppressor cells in multiple myeloma: mechanistic insights and therapeutic implications.Frontiers in immunology · 2026Review
- Enhancing immunotherapy efficacy in multiple myeloma and chronic lymphocytic leukemia: from combinatorial therapeutic approaches to gut microbiota modulation.Frontiers in immunology · 2026Review
- Pulmonary adverse events following immune checkpoint inhibitors.Current opinion in pulmonary medicine · 2022Review
- Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity.Cancers · 2021Review
- Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities.Cancers · 2021Review
- Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression.Cancers · 2021Review
- Bystander Memory T Cells and IMiD/Checkpoint Therapy in Multiple Myeloma: A Dangerous Tango?Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 11 institutions in 1 country.
Noemí PuigCancer Research Center (CiC-IBMCC, CSIC/USAL), Hematology Department, Center for Biomedical Research in Network of Cancer (CIBERONC), Institute of Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, 37008 Salamanca, Spain.
Luis A Corchete-SánchezCancer Research Center (CiC-IBMCC, CSIC/USAL), Hematology Department, Center for Biomedical Research in Network of Cancer (CIBERONC), Institute of Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, 37008 Salamanca, Spain.ORCID 0000-0003-4577-8599
José J Pérez-MoránCancer Research Center (CiC-IBMCC, CSIC/USAL), Hematology Department, Center for Biomedical Research in Network of Cancer (CIBERONC), Institute of Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, 37008 Salamanca, Spain.
Julio DávilaComplejo Asistencial de Ávila, Hematology Department, 05071 Ávila, Spain.ORCID 0000-0002-5185-2073
Teresa PaínoCancer Research Center (CiC-IBMCC, CSIC/USAL), Hematology Department, Center for Biomedical Research in Network of Cancer (CIBERONC), Institute of Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, 37008 Salamanca, Spain.ORCID 0000-0002-0201-3572
Javier de la RubiaHematology Service, University Hospital Peset and Internal Medicine, School of Medicine and Dentistry, Catholic University of Valencia, 46017 Valencia, Spain.ORCID 0000-0002-8354-768X
Albert OriolHematology Department, Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trials i Pujol, 08916 Badalona, Barcelona, Spain.ORCID 0000-0001-6804-2221
Jesús Martín-SánchezHematology Department, Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain.
Felipe de ArribaServicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, IMIB-Arrixaca, Universidad de Murcia, 30008 Murcia, Spain.
Joan BladéHematology Department, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi I Sunyer, 08036 Barcelona, Spain.
María-Jesús BlanchardHematology Department, Hospital Ramón y Cajal, 28034 Madrid, Spain.
Verónica González-CalleCancer Research Center (CiC-IBMCC, CSIC/USAL), Hematology Department, Center for Biomedical Research in Network of Cancer (CIBERONC), Institute of Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, 37008 Salamanca, Spain.ORCID 0000-0002-5493-6707
Ramón García-SanzCancer Research Center (CiC-IBMCC, CSIC/USAL), Hematology Department, Center for Biomedical Research in Network of Cancer (CIBERONC), Institute of Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, 37008 Salamanca, Spain.ORCID 0000-0003-4120-2787
Bruno PaivaCentro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Clínica Universidad de Navarra, CIBERONC, 31008 Pamplona, Spain.
Juan-José LahuertaCentro de Investigación Biomédica en Red Cáncer (CIBERONC), Instituto de Investigación, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.ORCID 0000-0002-3393-9570
Jesús F San-MiguelCentro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Clínica Universidad de Navarra, CIBERONC, 31008 Pamplona, Spain.
María-Victoria MateosCancer Research Center (CiC-IBMCC, CSIC/USAL), Hematology Department, Center for Biomedical Research in Network of Cancer (CIBERONC), Institute of Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, 37008 Salamanca, Spain.ORCID 0000-0003-2390-1218
Enrique M OcioHospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, 39008 Santander, Spain.ORCID 0000-0002-5765-0085
Instituto de Investigación Biomédica de Salamanca · ESNavarre Institute of Health Research · ESCatholic University of Ávila · ESCentro de Investigación Biomédica en Red de Cáncer · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESHospital General Universitario Morales Meseguer · ESHospital Universitario Ramón y Cajal · ESHospital Universitario Virgen del Rocío · ESInstitut Català d'Oncologia · ESUniversidad de Cantabria · ESUniversitat de València · ES
Funding
No grant is acknowledged in the PubMed record.
Abstract
PD1 expression in CD4
Indexed as
consolidationimmunotherapymyelomapembrolizumab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.